Method of delivering PESP/ICC as well as adjusting the refractory period of the heart

• US 8,046,064 B2
• Filed: 04/24/2006
• Issued: 10/25/2011
• Est. Priority Date: 04/24/2006
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Warkentin, Dwight H., Deno, D. Curtis
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): Bays; Pamela M
• Application Number:
  US11/379,892
• Publication Number:
  US 20070250122A1
• Time in Patent Office: 2,010 Days
• Field of Search: 607/9, 607/23, 607/17, 607/4, 607/5, 607/6, 607/14, 607/15
• US Class Current: 607/9
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36514 controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by two or more physical parameters A61N1/36585
• CPC Class Codes: A61N 1/36585 controlled by two or more physical parameters
• CPC Class Codes: A61N 1/368 comprising more than one electrode co-operating with different heart regions A61N1/3622, A61N1/3627 take precedence

Abstract

Medical devices and methods are used to treat cardiac dysfunction conditions which involve delivery of stimulation pulses in cardiac refractory periods in order to modulate an effective refractory period (ERP). Such devices and methods may be used in conjunction with or in place of other therapies, including increased cardiac contractility (ICC) therapy, post extrasystolic potentiation (PESP) therapy, and other therapies to achieve increased heart contractility, provide a safer and more effective regimen for the corresponding stimulation therapies, and reduce the risk of inducing an arrhythmia.

Claims

1. A medical device for treating cardiac dysfunction, comprising:

implantable sensor means for obtaining one or more cardiac parameters of a patient;

a processor means for processing the one or more cardiac parameters to determine whether cardiac dysfunction is present;

therapy delivery means for delivering therapies upon a determination of cardiac dysfunction being present, the delivered therapies comprising both stimulation of excitable tissue to treat the cardiac dysfunction and modulation of the excitable tissue'"'"'s effective refractory periods to achieve a desired effective refractory period; and

wherein the stimulation to treat the cardiac dysfunction comprises post extrasystolic potentiation, and wherein the refractory period modulation comprises refractory period stimulation shortening of one or more of an initial refractory period and a secondary refractory period.

2. A medical device according to claim 1, wherein the medical device comprises one or more of diagnostic monitoring equipment, an external medical device system, an implantable hemodynamic monitor, an implantable cardioverter-defibrillator, a cardiac pacemaker, a cardiac resynchronization therapy pacing device, and a drug delivery device.

3. A medical device according to claim 1, wherein the implantable sensor means comprise one or more of sense/pace electrodes, blood pressure sensors, accelerometers, impedance electrodes, flow probes, microphones, sonometric crystals, metabolic sensors, and chemical sensors.

4. A medical device according to claim 1, wherein the refractory period stimulation comprises a plurality of stimulation pulses, and wherein the plurality of stimulation pulses has a biphasic arrangement.

5. A medical device according to claim 1, wherein the stimulation to treat the cardiac dysfunction comprises delivery of a first one or more pulses and wherein the refractory period stimulation comprises delivery of a second one or more pulses having an adjustment to one or more of amplitude, duration, and frequency of the first one or more stimulation pulses.

6. A medical device according to claim 1, wherein the refractory period stimulation comprises shortening of both the initial refractory period and the secondary refractory period of the cardiac cycle.

7. A medical device according to claim 1,

wherein stimulation pulses of the refractory period stimulation have one or more of a higher amplitude, a higher duration, a lower polarity in part, and a higher frequency than stimulation pulses of the stimulation to treat the cardiac dysfunction.

8. A medical device for treating cardiac dysfunction, comprising:

implantable sensor means for obtaining one or more cardiac parameters of a patient;

a processor means for processing the one or more cardiac parameters to determine whether cardiac dysfunction is present;

therapy delivery means for delivering therapies upon a determination of cardiac dysfunction being present, the delivered therapies comprising;

non-excitory stimulation comprising delivery of a first one or more stimulation pulses to excitable tissue to treat the cardiac dysfunction; and

refractory period stimulation comprising delivery of a second one or more stimulation pulses to elongate the effective refractory period of the excitable tissue and

wherein the second one or more stimulation pulses have one or more of a lower amplitude, a lower duration, a higher polarity in part, and a lower frequency than that contained in the first one or more stimulation pulses.